Journal article
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Abstract
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case–control study. Control women were of …
Authors
Gronwald J; Robidoux A; Kim-Sing C; Tung N; Lynch HT; Foulkes WD; Manoukian S; Ainsworth P; Neuhausen SL; Demsky R
Journal
Breast Cancer Research and Treatment, Vol. 146, No. 2, pp. 421–427
Publisher
Springer Nature
Publication Date
July 2014
DOI
10.1007/s10549-014-3026-3
ISSN
0167-6806